CAJ | 학술논문

恶性胶质瘤的发生发展与受体酪氨酸激酶(RTK)过表达及其信号转导通路的异常激活密切相关,据此开发出的靶向治疗药物如RTK抑制剂、RTK下游信号通路抑制剂和多靶点抑制剂等能在分子水平上对恶性胶质瘤进行靶向性治疗,其中部分已通过临床试验,并取得良好疗效.
악성효질류적발생발전여수체락안산격매(RTK)과표체급기신호전도통로적이상격활밀절상관,거차개발출적파향치료약물여RTK억제제、RTK하유신호통로억제제화다파점억제제등능재분자수평상대악성효질류진행파향성치료,기중부분이통과림상시험,병취득량호료효.
The occurrence and development of malignant glioma are closely related to abnormal overexpression and activation of receptor tyrosine kinase (RTK) signal transduction pathways.Targeted therapeutic drugs such as RTK inhibitors,RTK downstream signaling pathway inhibitors and multi-target inhibitors can targeting treat malignant glioma at molecular level,some of which have been investigated in clinical trials and achieved good therapeutic effects.